Author

B. G. Vincent

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:proteomics· 3 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Approach:benchmark study· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Rubinsteyn· 2 shared C. C. Smith· 2 shared J. Garness· 2 shared M. Sambade· 2 shared A. D. Sahu· 1 shared A. S. Halkola· 1 shared A. Woods· 1 shared B. Carpenter· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Rubinsteyn

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

M. Mason, O. Lapuente-Santana, A. S. Halkola, W. Wang, R. Mall, X. Xiao, J. Kaufman, J. Fu, J. Pfeil, J. Banerjee, V. Chung, H. Chang, S. D. Chasalow, H. Y. Lin, R. Chai, , B. G. Vincent

The paper evaluates predictive models for immune checkpoint inhibitor outcomes in NSCLC using clinical trial data from two RCTs, finding that models combining PD-L1, TMB, and immune signatures outperform single biomarkers.

Journal of Translational Medicine · Feb 21, 2024Peer-reviewedCancer Biology

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab

E. D. Routh, M. G. Woodcock, J. S. Serody, B. G. Vincent

The paper evaluates antibody responses to tumor antigens in patients with metastatic triple negative breast cancer treated with pembrolizumab and cyclophosphamide, finding a link between antibody signal intensity and clinical response.

bioRxiv · Aug 19, 2022Cancer Biology

A SARS-CoV-2 peptide vaccine which elicits T-cell responses in mice but does not protect against infection or disease

V. K. Baxter, E. J. Anderson, S. A. Taft-Benz, K. S. Olsen, M. Sambade, K. M. Gentry, W. A. Beck, J. Garness, A. Woods, M. Fini, B. Carpenter, C. C. Smith, M. T. Heise, B. G. Vincent, A. Rubinsteyn

This study evaluates a SARS-CoV-2 peptide vaccine in mice, finding it induces T-cell responses but fails to prevent infection or disease.

bioRxiv · Feb 22, 2022 · PreprintImmunology

Landscape and Selection of Vaccine Epitopes in SARS-CoV-2

C. C. Smith, S. Entwistle, C. Willis, S. Vensko, W. Beck, J. Garness, M. Sambade, E. Routh, K. Olsen, J. Kodysh, T. O'Donnell, C. Haber, K. Heiss, V. Stadler, E. Garrison, , A. Rubinsteyn

This study identifies vaccine epitopes in SARS-CoV-2 by combining computational T cell epitope prediction, B cell epitope mapping, and manufacturability criteria to propose candidate peptides for further testing.

bioRxiv · Jun 4, 2020Immunology